Filing Details
Aktis Oncology, Inc. (NASDAQ:AKTS) filed its quarterly report (Form 10-Q) with the Securities and Exchange Commission on November 12, 2026.
The Healthcare company reported Q0 revenue of .
Aktis Oncology, Inc. (NASDAQ:AKTS) filed its quarterly report (Form 10-Q) with the Securities and Exchange Commission on November 12, 2026.

At publication ·
Aktis Oncology, Inc. (NASDAQ:AKTS) · 10q filed
At a glance
Aktis Oncology, Inc. (NASDAQ:AKTS) filed its quarterly report (Form 10-Q) with the Securities and Exchange Commission on November 12, 2026.
The Healthcare company reported Q0 revenue of .
Aktis Oncology, Inc.'s stock currently trades at $17.04 with a market capitalization of $1.1B.
The 10-Q provides Aktis Oncology, Inc.'s quarterly financial update, including unaudited financial statements and management commentary on recent performance. While less detailed than the annual 10-K, the 10-Q often contains timely information about emerging trends, updated risk factors, and changes in business conditions since the last filing.
All SEC filings for Aktis Oncology, Inc. are publicly available through the SEC's EDGAR database. Investors can set up alerts for new filings to stay current on material developments.
Related Tools: View AKTS Stock Page
Browse all filings on our AKTS SEC filings page.
Public companies like Aktis Oncology, Inc. file annual reports (10-K), quarterly reports (10-Q), material events (8-K), and insider transactions (Form 4) with the SEC.
Current market data
NASDAQ · AKTS
$16.16
Down: -$0.46 · -2.77%
Live quote updated
Keep reading